Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.

@article{Liu2012SorafenibIH,
  title={Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.},
  author={Li-ping Liu and Rocky L. K. Ho and George Gong Chen and Paul B. S. Lai},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 20},
  pages={5662-71}
}
PURPOSE The overexpression of hypoxia-inducible factor 1α (HIF-1α) is a common finding in hepatocellular carcinoma (HCC), and it leads to angiogenesis and poor prognosis. Sorafenib, a multikinase inhibitor, has shown significant improvement in survival in patients with advanced HCC in clinical trials. However, the mechanisms that account for the antiangiogenic efficiency of sorafenib have not been fully elucidated. The present study aims to explore the effect of sorafenib on HIF-1α expression… CONTINUE READING
33 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Epidermal growth factor receptor andHER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells

  • MJ Blivet-Van Eggelpoel, H Chettouh, L Fartoux, L Aoudjehane, V Barbu, ReyC
  • J Hepatol 2012;57:108–15
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…